According to the report of the Eiffe News Agency, British researchers have, for the first time in a groundbreaking study, transfused blood cultivated in the laboratory to healthy volunteers, which may completely change the treatment of patients with blood diseases. On November 7, Ashley Toy, a scholar at the University of Bristol, said in a statement that the clinical trial was "an important step towards stem cell hematopoiesis", but he also said that further research was needed to verify the feasibility of this method. So far, in this study called RESTORE, two people have received blood transfusion (equivalent to one or two teaspoons of blood) from laboratory cultured red blood cells. The study involved a number of British universities and health organizations. The statement said that both of them were under close monitoring and had not found any side effects. As part of this clinical trial, at least 10 participants will receive two "mini blood transfusions" at least 4 months apart, one is donated normal red blood cells, the other is red blood cells cultured in the laboratory. This test attempts to determine the effective life of young, laboratory cultured cells and compare it with standard blood transfusions from donors containing cells of different ages. The researchers said that if it is proved that the blood cells cultured in the laboratory can survive longer in the body, "then patients who need regular blood transfusion may be able to reduce the frequency of blood transfusion". The authors of the study said that artificial cultivation of red blood cells could "revolutionize the treatment of patients with sickle cell anemia or blood diseases with rare blood types". They said that the test "is the first step in the future to use laboratory cultured red blood cells as clinical products", although they will initially be used in "a few patients with complex blood transfusion needs". (Liu Xinshe)